Hermetica Superfood Encyclopedia
The Short Answer
Phellinus linteus produces phenylpropanoids—including hispidin, inotilone, caffeic acid, and 3,4-dihydroxybenzalacetone (DBL)—alongside polysaccharides that collectively inhibit NF-κB and MAPK signaling, modulate TLR4/PI3K-AKT pathways, and suppress pro-inflammatory cytokine cascades. Preclinical evidence demonstrates dose-dependent antioxidant activity superior to BHA and Trolox in ferric reducing assays, antitumor effects in cell lines and animal models, and anti-inflammatory activity at DBL doses of 5 mg/kg in rodent models, though human clinical trial data remain absent.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary KeywordPhellinus linteus benefits
Meshima — botanical close-up
Health Benefits
**Antitumor Activity**
Compounds meshimakobnol A/B, phellifuropyranone A, hispidin, and polysaccharide fractions have demonstrated cytotoxic and antiproliferative effects in tumor cell lines and animal models, likely via immune activation and direct induction of apoptotic pathways.
**Immune Modulation**
High-molecular-weight polysaccharides and beta-glucans from the fruiting body stimulate macrophage activation and natural killer cell function, supporting adjunct use in immune-compromised conditions.
**Anti-Inflammatory Effects**
DBL (3,4-dihydroxybenzalacetone) suppresses LPS-induced NO production and pro-inflammatory cytokines (TNF-α, IL-6) in RAW 264.7 macrophages by blocking TLR4 engagement and downstream PI3K/AKT and MAPK signaling at 5 mg/kg in rodent models.
**Antioxidant Protection**
Caffeic acid, inotilone, and 4-(3,4-dihydroxyphenyl)-3-buten-2-one possess catechol moieties that donate hydrogen atoms to neutralize free radicals, outperforming synthetic antioxidants BHA and Trolox in standardized ferric reducing antioxidant power (FRAP) assays.
**Antidiabetic Potential**
Aldose reductase inhibitors isolated from Phellinus linteus (compounds 5, 7, and 13) exhibit IC50 values of 0.33–1.37 μM against both rat lens and human recombinant aldose reductase, potentially preventing sorbitol accumulation in diabetic complications. Compounds 4, 8, 9, and 11 additionally inhibit hemoglobin A1c formation and methylglyoxal-mediated protein glycation.
**Neuroprotective Effects**
Hispidin acts as a noncompetitive inhibitor of β-secretase (BACE1), the enzyme responsible for amyloidogenic cleavage of amyloid precursor protein, suggesting a potential mechanistic role in reducing amyloid-beta peptide generation relevant to Alzheimer's pathology.
**Antimicrobial Activity**
Ethyl acetate extracts demonstrated antimicrobial activity against Bacillus subtilis at a minimum inhibitory concentration of 10 mg/mL in vitro, with phenylpropanoid constituents proposed as primary contributors to this antibacterial effect.
Origin & History
Natural habitat
Phellinus linteus is a bracket fungus native to Asia, growing parasitically on white mulberry trees (Morus alba) across China, Korea, and Japan, where it has been harvested from mature hardwood forests for centuries. It produces woody, hoof-shaped fruiting bodies with a dark outer crust and golden-brown inner flesh, favoring humid temperate forest environments. Modern cultivation employs controlled conditions including specific light regimens, humidity gradients, regulated CO2 levels, and temperature management to optimize mycelium growth and bioactive compound accumulation in submerged liquid culture broth.
“Phellinus linteus has been used for over a millennium in traditional Chinese, Korean, and Japanese medicine, where it is revered as 'Sanghwang' in Korea and 'Meshima' in Japan—terms reflecting its growth on mulberry trees and its cultural association with longevity and cancer resistance. In traditional East Asian oncology practice, it was prescribed as a decoction alongside other medicinal mushrooms and herbs to strengthen the body's defensive energy (wei qi in Traditional Chinese Medicine) and counteract malignant growths, earning it status as one of the most prized medicinal fungi in the Asian materia medica. Korean court records and classical pharmacopeias including the Dongui Bogam (1613 CE) reference mushroom-based preparations with properties consistent with Phellinus linteus for inflammatory and wasting conditions. Its extreme rarity in wild form—owing to its dependence on mature mulberry trees—historically made it a luxury medicinal, with modern cultivation technology only recently making bioactive study materials accessible at scale.”Traditional Medicine
Scientific Research
The totality of published research on Phellinus linteus consists predominantly of in vitro cell culture experiments and small rodent in vivo models, with no peer-reviewed randomized controlled trials in human subjects identified in the available literature. Preclinical antitumor data derive from tumor cell line assays and xenograft animal models using isolated compounds such as meshimakobnol A/B and phellifuropyranone A, while anti-inflammatory efficacy was demonstrated in LPS-challenged RAW 264.7 macrophage models and rodent inflammatory models at 5 mg/kg DBL. Aldose reductase inhibition data represent biochemical enzyme assays with defined IC50 values (0.33–1.37 μM), which while precise, have not been translated to pharmacokinetic or pharmacodynamic outcomes in humans. The evidence base, while mechanistically detailed at the molecular level, is insufficient to establish efficacy, optimal dosing, or safety in clinical populations, and the ingredient must be regarded as a preclinical-stage candidate requiring rigorous human trials.
Preparation & Dosage
Traditional preparation
**Dried Fruiting Body Powder**
Traditionally consumed as a decoction or powder; no standardized human dose established; animal studies use extracts rather than whole powder.
**Ethyl Acetate Extract**
Used in the majority of preclinical studies to isolate phenylpropanoid compounds; extraction standardization for commercial products is not yet defined.
**Mycelium Culture Broth Extract**
Rich in phellilane H, ionylideneacetic acid derivatives, and inotilone; produced via submerged liquid fermentation under controlled light, humidity, CO2, and temperature.
**Polysaccharide-Rich Extract**
Beta-glucan and polysaccharide fractions studied for immune modulation; typical experimental concentrations range broadly without an established human equivalency dose.
**Traditional Decoction**
Fruiting bodies simmered in water for extended periods (1–3 hours); used in East Asian herbal medicine as a tea or concentrated liquid.
**Standardization Note**
No commercially agreed-upon standardization marker (e.g., percent hispidin or polysaccharide content) has been established; consumers should seek products specifying beta-glucan or polysaccharide percentage as a proxy quality marker.
**Timing**
No human pharmacokinetic data exist to guide optimal timing of administration.
Nutritional Profile
Phellinus linteus fruiting bodies contain beta-glucan polysaccharides as primary macromolecular bioactives, alongside chitin-based dietary fiber contributing to the structural matrix. Key phytochemicals include phenylpropanoids (hispidin, caffeic acid, inotilone, DBL, 4-(3,4-dihydroxyphenyl)-3-buten-2-one), terpenoids (phellilane H, phellilane L, ionylideneacetic acid derivatives), and polyhydroxylated aldose reductase inhibitors; specific concentrations in dried material are not standardized in the literature. Trace minerals characteristic of wood-degrading bracket fungi (including potassium, magnesium, and iron) are present, though quantitative nutritional analyses specific to Phellinus linteus are sparse compared to better-studied culinary mushrooms. Bioavailability of polysaccharide fractions is expected to be limited by their high molecular weight and susceptibility to gastrointestinal degradation, while small-molecule phenylpropanoids such as caffeic acid have established intestinal absorption mechanisms via sodium-dependent active transport and passive diffusion.
How It Works
Mechanism of Action
The phenylpropanoid DBL suppresses inflammatory signaling by inhibiting Toll-like receptor 4 (TLR4) activation, thereby blocking downstream recruitment of PI3K/AKT and MAPK (ERK1/2, p38, JNK) cascades, which collectively reduce transcriptional activation of NF-κB and subsequent production of nitric oxide and pro-inflammatory cytokines in macrophages. Hispidin functions as a noncompetitive inhibitor of β-secretase (BACE1), binding at an allosteric site to reduce proteolytic processing of amyloid precursor protein independent of substrate concentration. The catechol functional groups present in caffeic acid, inotilone, and 4-(3,4-dihydroxyphenyl)-3-buten-2-one directly scavenge reactive oxygen species via single-electron transfer and hydrogen atom donation, with their ortho-dihydroxy configuration conferring superior electron-donating capacity relative to monohydroxy antioxidants. Aldose reductase inhibition by isolated polyhydroxylated compounds (IC50 0.33–1.37 μM) prevents NADPH-dependent reduction of glucose to sorbitol, while separate inhibition of methylglyoxal-mediated glycation targets a parallel advanced glycation end-product formation pathway linked to diabetic neuropathy and nephropathy.
Clinical Evidence
No randomized controlled trials, phase I/II clinical studies, or observational cohort studies with quantified human outcomes have been reported for Phellinus linteus as of the available research data. The preclinical pharmacological profile is detailed, with defined IC50 values for enzyme inhibition, effective doses in rodent inflammatory models (5 mg/kg DBL), and antioxidant capacity superior to reference standards in ferric reducing assays. Traditional use across China, Korea, and Japan provides centuries of empirical support for immune and anticancer applications, but this does not substitute for controlled clinical evidence. Confidence in efficacy claims for human supplementation remains low, and any therapeutic application should be regarded as investigational pending adequately powered clinical trials.
Safety & Interactions
Formal toxicological studies, maximum tolerated dose determinations, and systematic adverse event reporting for Phellinus linteus in humans are absent from the published literature, making a complete safety profile impossible to construct at this time. The in vitro antimicrobial effective concentration of 10 mg/mL and the absence of reported toxicity signals in preclinical animal experiments at doses up to 5 mg/kg suggest a tentatively low acute toxicity profile, but this cannot be extrapolated to chronic human supplementation without dedicated safety studies. Potential drug interactions are theoretically plausible given the inhibition of NF-κB and PI3K/AKT pathways—pathways targeted by immunosuppressants and certain oncology agents—suggesting caution in individuals receiving corticosteroids, calcineurin inhibitors, mTOR inhibitors, or cytotoxic chemotherapy. No safety data exist for use during pregnancy, lactation, or in pediatric populations, and these groups should avoid supplementation until dedicated safety research is available.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Phellinus linteusMeshimaSanghwangMulberry Yellow PolyporeInonotus linteus
Frequently Asked Questions
What is Phellinus linteus used for?
Phellinus linteus is used traditionally in East Asian medicine for immune support, cancer adjunct therapy, and anti-inflammatory applications. Its key bioactives—including polysaccharides, hispidin, and DBL—have demonstrated antitumor, antioxidant, and anti-inflammatory effects in preclinical cell and animal studies, though human clinical trials are not yet available to confirm these benefits.
What are the active compounds in Phellinus linteus?
The primary bioactive compounds include phenylpropanoids (hispidin, caffeic acid, inotilone, 3,4-dihydroxybenzalacetone/DBL), terpenoids (phellilane H, phellilane L), and high-molecular-weight beta-glucan polysaccharides. Caffeic acid, inotilone, and DBL show particularly potent antioxidant activity superior to BHA and Trolox in ferric reducing assays, while hispidin inhibits the Alzheimer's-associated enzyme β-secretase noncompetitively.
Is there clinical trial evidence for Phellinus linteus in cancer treatment?
As of current published data, no randomized controlled trials or phase I/II human clinical studies have been completed for Phellinus linteus in cancer treatment. Antitumor evidence is limited to cell line experiments and animal xenograft models using isolated compounds such as meshimakobnol A/B and phellifuropyranone A; these findings are promising but cannot be used to make efficacy claims in human oncology without controlled clinical research.
What is the recommended dosage of Phellinus linteus?
No standardized human supplemental dose for Phellinus linteus has been established in clinical trials. Preclinical anti-inflammatory studies used DBL at 5 mg/kg in rodents, but this cannot be directly converted to a human equivalent dose without pharmacokinetic data. Traditional preparations involved decoctions of dried fruiting bodies, and commercial products should ideally specify polysaccharide or beta-glucan content as a quality benchmark.
Are there any side effects or drug interactions with Phellinus linteus?
Formal human safety data for Phellinus linteus are currently unavailable, and no systematic adverse event reporting exists. Theoretical drug interactions are possible with immunosuppressants (e.g., cyclosporine, tacrolimus) and oncology medications due to overlapping NF-κB and PI3K/AKT pathway effects. Pregnant and breastfeeding individuals should avoid use until dedicated safety research establishes a risk profile.
What is the difference between Phellinus linteus fruiting body and mycelium extracts?
Fruiting body extracts of Phellinus linteus contain higher concentrations of bioactive polysaccharides and beta-glucans compared to mycelium-based products, making them generally more potent for immune modulation. Fruiting body extracts have been the primary focus of clinical research demonstrating antitumor and immunostimulatory effects, whereas mycelium extracts are less well-studied for these specific benefits. The fruiting body also contains hispidin and other phenolic compounds at meaningful levels that contribute to the mushroom's biological activity.
Who should avoid taking Phellinus linteus supplements?
Individuals with mushroom allergies or mold sensitivities should avoid Phellinus linteus due to cross-reactivity risks. People taking immunosuppressant medications (such as those used post-organ transplant) should consult a healthcare provider before use, as the mushroom's potent immune-stimulating polysaccharides may counteract these medications. Pregnant and nursing women should seek medical guidance before supplementation, as safety data in these populations remains limited.
How does the processing method of Phellinus linteus affect its bioavailability?
Hot water extraction and standardized polysaccharide extracts of Phellinus linteus are more bioavailable than whole fruiting body powders because the extraction process breaks down the fungal cell wall, making beta-glucans and polysaccharides more readily absorbed by the digestive system. Dual extraction methods (combining hot water and alcohol) may increase the availability of both water-soluble polysaccharides and lipophilic compounds like hispidin. Particle size reduction and fermentation preprocessing can further enhance bioavailability compared to raw, unprocessed mushroom material.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w phellinus-linteus-phellinus-linteus curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
